Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients

Status:
Recruiting

Trial end date:
2024-12-28

Target enrollment:

Participant gender:

To assess the efficacy and safety of 0.5mg Fingolimod (Gilenya) in Chinese patients with relapsing relapsing multiple sclerosis (RMS)

Phase 4

Novartis Pharmaceuticals

Fingolimod Hydrochloride